Stifel analyst Daniel Arias maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $680 to $665.
According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of -9.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
The company delivered results that matched market anticipations amid heightened expectations. There is recognition of the company's strong execution within a challenging tools demand climate, coupled with a current lack of clarity regarding the timing of demand resurgence.
The company's third-quarter earnings discussion was seen as more optimistic than actual results, and there remains a positive outlook on the stock. This is due to sustained momentum in the Life Sciences Solutions segment and stable sales within the Laboratory Products and Biopharma Services segment, which appears to be resilient to the biotech downturn.
Thermo Fisher is showing a consistent improvement in core growth with quarter-over-quarter increments, and projections suggest a modest rise to approximately +2.5% in the fourth quarter. Expectations for a 5% core growth rate in 2025 appear to be reasonable and justifiable. The company's defensive profile and the potential of its balance sheet continue to be favorable aspects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Daniel Arias維持$賽默飛世爾 (TMO.US)$買入評級，並將目標價從680美元下調至665美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.3%，總平均回報率為-9.8%。
此外，綜合報道，$賽默飛世爾 (TMO.US)$近期主要分析師觀點如下：
公司交付了符合市場預期的業績，在預期增長的背景下。對於在需求挑戰性工具氣候中表現出色的公司執行力有所認可，同時目前對需求復甦的時間缺乏清晰的認識。
公司第三季度收益討論被認爲比實際結果更爲樂觀，對該股票仍持積極態度。這是由於在生命科學解決方案部門維持的勢頭和實驗室產品與生物製藥服務部門內部穩定的銷售，後者似乎對生物技術行業的衰退具有抵禦力。
賽默飛世爾正在展現核心增長持續改善，季度間遞增，預計第四季度將略有增長至約+2.5%。對於2025年達到5%核心增長率的預期似乎是合理且有可能的。公司的防禦性配置和資產負債表潛力依然是有利因素。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
